Evidence map›Paper›PMID 27658492›Full record

ArticleBMC cancer2016

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.

Archana Anantharaman, Terence Friedlander, David Lu, Rachel Krupa, Gayatri Premasekharan, Jeffrey Hough, Matthew Edwards, Rosa Paz, Karla Lindquist, Ryon Graf and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 2 pooled it
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Varied functions of immune checkpoints during cancer metastasis.Cancer immunology, immunotherapy : CII · 2021
    Review
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Archana AnantharamanDivision of Hematology-Oncology, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, 1825 4th Street, 6th Floor, San Francisco, CA, 94158, USA.
Terence FriedlanderDivision of Hematology-Oncology, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, 1825 4th Street, 6th Floor, San Francisco, CA, 94158, USA. Terence.Friedlander@ucsf.edu.ORCID http://orcid.org/0000-0002-3630-4941
David LuEpic Sciences, San Diego, CA, USA.
Rachel KrupaEpic Sciences, San Diego, CA, USA.
Gayatri PremasekharanDepartment of Urology, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA, USA.
Jeffrey HoughDivision of Hematology-Oncology, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, 1825 4th Street, 6th Floor, San Francisco, CA, 94158, USA.
Matthew EdwardsDivision of Hematology-Oncology, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, 1825 4th Street, 6th Floor, San Francisco, CA, 94158, USA.
Rosa PazDivision of Hematology-Oncology, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, 1825 4th Street, 6th Floor, San Francisco, CA, 94158, USA.
Karla LindquistDepartment of Urology, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA, USA.
Ryon GrafEpic Sciences, San Diego, CA, USA.
Adam JendrisakEpic Sciences, San Diego, CA, USA.
Jessica LouwEpic Sciences, San Diego, CA, USA.
Lyndsey DuganEpic Sciences, San Diego, CA, USA.
Sarah BairdEpic Sciences, San Diego, CA, USA.
Yipeng WangEpic Sciences, San Diego, CA, USA.
Ryan DittamoreEpic Sciences, San Diego, CA, USA.
Pamela L ParisDivision of Hematology-Oncology, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, 1825 4th Street, 6th Floor, San Francisco, CA, 94158, USA.
Epic Sciences (United States) · USUCSF Helen Diller Family Comprehensive Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) checkpoint inhibitors have activity in a proportion of patients with advanced bladder cancer, strongly predictive and prognostic biomarkers are still lacking. In this study, we evaluated PD-L1 protein expression on circulating tumor cells (CTCs) isolated from patients with muscle invasive (MIBC) and metastatic (mBCa) bladder cancer and explore the prognostic value of CTC PD-L1 expression on clinical outcomes.

methodsBlood samples from 25 patients with MIBC or mBCa were collected at UCSF and shipped to Epic Sciences. All nucleated cells were subjected to immunofluorescent (IF) staining and CTC identification by fluorescent scanners using algorithmic analysis. Cytokeratin expressing (CK)

resultsCTCs were detected in 20/25 (80 %) patients, inclusive of CK

conclusionsCTCs are detectable in both MIBC and mBCa patients. PD-L1 expression is demonstrated in both CK

Indexed as

BiomarkersBladder cancerCirculating tumor cellsLiquid biopsyPD-L1

Identifiers

PMID27658492
PMCPMC5034508
OpenAlexW2522277066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.